Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO)
Latest Information Update: 28 Jul 2022
At a glance
- Drugs Bamlanivimab (Primary) ; Etesevimab (Primary) ; Sotrovimab (Primary) ; Casirivimab/imdevimab
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms MANTICO
Most Recent Events
- 07 Apr 2022 Status changed from recruiting to discontinued.
- 19 Aug 2021 New trial record